BAVA Bavarian Nordic A/S

CPH · DK · Healthcare · Biotechnology · bavarian-nordic.com

218.40DKK+0.65%Mkt Cap: 2.38B $P/E: 11.19Today

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human u…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap2.38B USD

Enterprise Value2.07B USD

Revenue (TTM)923.16M USD

Gross Profit444.04M USD

Net Income (TTM)200.33M USD

Revenue/Share79.88 DKK

Last Price218.40 DKK

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees1.9K

CountryDK

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)11.19

P/E (Forward)20.63

PEG1.87

EV/EBITDA7.96

EV/Revenue2.24

P/S2.58

P/B1.25

EPS (TTM)19.50

EPS (Forward)10.52

52W Range

171.3065% of range243.70

52W High243.70 DKK

52W Low171.30 DKK

Profitability

Gross Margin48.83%

Oper. Margin36.80%

EBITDA Margin28.12%

Profit Margin22.03%

ROE10.69%

ROA9.20%

Growth

Revenue Growth23.20%

Earnings Growth169.70%

Cash Flow & Leverage

Operating CF396.45M USD

CapEx (TTM)197.98M USD

FCF Margin1.73%

FCF Yield0.67%

Net Debt-324.34M USD

Net Debt/EBITDA-1.25

Balance Sheet

Debt/Equity0.01

Current Ratio6.53

Quick Ratio3.83

Book Value/Sh174.00 DKK

Cash/Share31.16 DKK

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 DKK

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)276.25 DKK

Upside (mean)+26.5%

Target Range265.00 DKK – 290.00 DKK

265.00+26.5% to mean290.00

# Analysts4

Ownership

Shares Out.75.25M

Float75.63M

Insiders0.01%

Institutions35.86%

Technical

SMA 50200.87 (+8.7%)

SMA 200192.58 (+13.4%)

Beta0.96

S&P 52W Chg14.58%

Avg Vol (30d)207.60K

Avg Vol (10d)162.04K

Technical Indicators

RSI (14)59.6

MACD4.7724

MACD Signal4.8475

MACD Hist.-0.0751

BB Upper226.07 DKK

BB Middle211.41 DKK

BB Lower196.75 DKK

BB Width13.87%

ATR (14)4.729 DKK

Vol Ratio (20d)0.74x